Budapest Vegyimuvek Expectations

18 December 1995

Budapest Vegyimuvek, a Hungarian producer of intermediaries for the pharmaceutical and chemical industries, expects sales for 1995 of 3.8 billion Hungarian forint ($27.5 million), with exports of 840 million forint. Operating profits for the year are expected to be 300 million forint, and pretax profits are forecast at 50 million forint.

In 1996, the firm expects to achieve sales of 4.5 billion forint, with exports of 1.2 billion forint. The firm is to issue bonds worth between 100 million and 300 million forint to finance its business development. The subscription period began December 11 and closes January 10, 1996.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight